Sandoz, which made a significant investment in bio-similars as a way to differentiate itself from its generic drug industry peers, has to negotiate with its parent company and the innovative pharma division on how best to commercialize its bio-similar portfolio. What is the best way to balance the parenting advantage of Novartis with the unique demands of the generic drug industry?

【書誌情報】

ページ数：24ページ

サイズ：A4

商品番号：HBSP-114033

発行日：2014/3/10

登録日：2016/6/8